GlassScriptPhysician profile
James Inho Rho
NPI 1548323769
$35,862.54
in general payments reported to CMS, 2019-2025
76 companies · $4,616 in 2025
The $4,616 reported for 2025 was more than what 90% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,201 · 2020: $3,702 · 2021: $6,765 · 2022: $4,796 · 2023: $5,375 · 2024: $4,408 · 2025: $4,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $33.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,364.60 |
| Education | $33.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,605.49 | 2019-2024 | Proclaim, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,861.48 | 2019-2025 | Relistor |
| Spinal Simplicity, LLC | $2,562.92 | 2021-2025 | Ha Minuteman G3-R |
| Pfizer INC. | $2,283.86 | 2019-2025 | |
| Abbvie INC. | $2,240.55 | 2021-2025 | |
| Forte Bio-Pharma LLC | $1,812.48 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Medtronic, INC. | $1,559.12 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Osteocool Rf Ablation System |
| Collegium Pharmaceutical, INC. | $1,242.64 | 2019-2025 | Xtampza, Belbuca |
| Amgen INC. | $1,073.64 | 2019-2023 | Aimovig |
| Boston Scientific Corporation | $1,033.39 | 2020-2025 | Intracept, Superion Indirect Decompression System, Wavewriter Alpha Prime 16 |
| Spr Therapeutics, INC | $669.18 | 2022-2023 | Sprint Pns System |
| Scilex Pharmaceuticals INC. | $648.92 | 2019-2025 | Ztlido |
| Lundbeck LLC | $629.77 | 2020-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $609.05 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $553.62 | 2019-2025 | Ajovy, Austedo Xr |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $526.32 | 2019-2025 | Trintellix |
| Nevro Corp. | $498.26 | 2019-2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $491.06 | 2022 | |
| Virtus Pharmaceuticals LLC | $462.67 | 2023-2025 | Levorphanol Tartrate |
| Daiichi Sankyo INC. | $453.19 | 2019 | |
| Lilly USA, LLC | $435.32 | 2019-2024 | Emgality |
| Vertiflex, INC. | $417.26 | 2019 | |
| Indivior INC. | $398.87 | 2019-2020 | |
| Saluda Medical Americas, INC. | $385.78 | 2023-2025 | Evoke, Evoke Scs |
| Si-Bone, INC. | $376.74 | 2019-2024 | |
| Axsome Therapeutics, INC. | $376.38 | 2022-2025 | Symbravo, Auvelity |
| Zyla Life Sciences, INC. | $346.12 | 2019-2020 | |
| Allergan, INC. | $334.17 | 2019-2020 | |
| Protega Pharmaceutials INC | $324.80 | 2025 | Roxybond |
| Almatica Pharma LLC | $319.87 | 2020-2023 | Gralise |
| Eisai INC. | $310.86 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $259.24 | 2019-2022 | |
| Foundation Fusion Solutions, LLC | $248.15 | 2023-2025 | |
| Globus Medical, INC. | $245.83 | 2025 | Senza, Vyrsa V1 |
| Mml US, INC. | $237.11 | 2023 | Reactiv8 |
| Nalu Medical, INC. | $224.91 | 2023-2025 | Nalu Neurostimulation System |
| Horizon Therapeutics Plc | $212.42 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $201.54 | 2020-2022 | |
| Relievant Medsystems, INC. | $192.01 | 2021-2023 | Intracept |
| Merck Sharp & Dohme LLC | $191.45 | 2020-2023 | Belsomra |
| Kowa Pharmaceuticals America, INC. | $177.65 | 2022-2023 | Seglentis |
| Biodelivery Sciences International, INC. | $174.58 | 2019-2021 | |
| Painteq LLC | $172.81 | 2022-2024 | Painteq |
| Grt US Holding, INC. | $170.57 | 2022 | |
| Redhill Biopharma INC. | $157.14 | 2020-2022 | |
| Curonix LLC | $154.13 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Phathom Pharmaceuticals, INC. | $150.58 | 2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $146.40 | 2019-2021 | |
| Trevena, INC. | $134.37 | 2021 | |
| Impel Pharmaceuticals INC. | $130.64 | 2023 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $123.65 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $105.63 | 2023-2025 | Quviviq, Quviviq |
| Assertio Therapeutics, INC. | $104.76 | 2019-2020 | |
| Depuy Synthes Sales INC. | $102.98 | 2019 | |
| Mdd US Operations, LLC | $101.76 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $92.11 | 2023-2025 | Horizant, Horizant |
| Averitas Pharma INC. | $89.02 | 2025 | Qutenza |
| Medtronic USA, INC. | $75.26 | 2019 | |
| Shionogi INC | $72.28 | 2019 | |
| Ibsa Pharma INC. | $70.13 | 2020-2024 | Tirosint, Tirosint, Licart |
| Valinor Pharma, LLC | $59.35 | 2024 | Movantik |
| Astrazeneca Pharmaceuticals LP | $59.07 | 2019-2020 | |
| Fidia Pharma USA INC. | $52.60 | 2019-2025 | Hymovis |
| Otsuka America Pharmaceutical, INC. | $41.16 | 2023 | Rexulti |
| Uswm, LLC | $38.10 | 2021-2022 | |
| Kaleo, INC. | $37.82 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $34.71 | 2024 | |
| Sentynl Therapeutics, INC. | $31.36 | 2019 | |
| Tonix Medicines, INC. | $23.78 | 2025 | Zembrace Symtouch |
| Sun Pharmaceutical Industries INC. | $21.85 | 2020 | |
| Stryker Corporation | $18.94 | 2019 | |
| Vision Quest Industries INC. | $18.85 | 2024 | Pro Estim Nmes Stimulator |
| Avanos Medical | $17.17 | 2019 | |
| Impel Pharmaceuticals LLC | $17.06 | 2024 | Trudhesa |
| Stimwave Technologies Incorporated | $15.00 | 2019 | |
| Fortovia Therapeutics, INC. | $12.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.